Notícias

The fair value estimate for Ionis Pharmaceuticals has shifted from US$96.73 to US$100.92, a modest reset that puts fresh numbers around the stock. This move comes during an active period of Street research, with some firms lifting targets and others trimming them, reflecting different views on how to factor pipeline milestones and revenue guidance into valuation work. As you read on, you will see what is driving these updates and how to keep track of the evolving analyst narrative around...

Citigroup Inc. (NYSE:C) is one of the best 52-week high stocks to invest in, according to short sellers. On May 22, Reuters reported that Citigroup Inc. (NYSE:C) plans to direct much of its global wealth management hiring to Asia, where its private bank is expanding faster and proving more productive than in other regions. Global […]

Citigroup eyes revenue growth through 2026 as loan demand, private credit expansion and transformation efforts support momentum.

Can C's restructuring and lower valuation give it the edge over GS in the race for banking growth in 2026? Let us find out.

JPM CEO Jamie Dimon says the bank could deploy up to $20B for the right deal, boosting growth options but raising execution and regulatory risks. Is the stock a buy?

Here is how Citigroup (C) and BGC Group (BGC) have performed compared to their sector so far this year.

We recently compiled a list of the 12 Best Strong Buy Tech Stocks to Invest In Now. CACI International Inc (NYSE:CACI) is one of the best Strong Buy stocks on this list. TheFly reported on May 18 that Citi reduced its price target on CACI to $555 from $614 while maintaining a Neutral rating on the stock. […]

GoodRx Holdings is back in focus after a fair value estimate was raised to US$3.18 from US$2.82, putting fresh attention on where the stock might fit in your watchlist. Some analysts have moved price targets toward US$4 while others have pulled them down into the US$2 to US$3 range, reflecting very different reads on recent guidance and the business mix. Keep reading to see what is driving that split view and how you can follow the evolving narrative around GoodRx. Analyst Price Targets don't...

Bill Ackman finally took the keys to Pershing Square public in April, and Wall Street is now beginning to weigh in on what that company is actually worth. Citi was the first major bank to argue it could be worth a lot more than the market currently thinks. On Tuesday, May 26, the firm initiated ...

The updated analyst fair value estimate for Ciena has shifted from US$378.11 to US$452.12, signaling a reset in what some models suggest the stock could be worth. This change sits alongside research that highlights stronger expectations around optical networking demand tied to data center and AI infrastructure spending, while also reflecting debate over how much of that story is already in the price. As you read on, you will see how this evolving narrative is taking shape and what to watch...

Citigroup (C) reached $125.27 at the closing of the latest trading day, reflecting a -1.25% change compared to its last close.

null

According to the average brokerage recommendation (ABR), one should invest in Citigroup (C). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The company is expanding how its customers can use artificial intelligence within Robinhood’s platform.

Huawei's Meng Wanzhou, Microsoft's Amy Hood, Meta's Susan Li, Alphabet's Anat Ashkenazi, and Nvidia's Colette Kress all land in the top 50.

(Bloomberg) -- It began as a concession in private conversations to assuage wary credit analysts looking at Paramount Skydance Corp.’s blockbuster takeover of Warner Bros. Discovery Inc.: a verbal pledge by the Ellison family to do whatever it takes to slash debt at the combined company.Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarSingapore Hands Byju's Founder His First Ever Jail TermPutin Signs Law on Use of Army to Aid Russians Detained AbroadRussia

(Bloomberg) -- Warner Bros. Discovery Inc. tightened pricing on its loan offering on Wednesday, a day after upsizing the deal to around $15 billion, as investor appetite for corporate credit allows borrowers to set favorable terms.Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarSingapore Hands Byju's Founder His First Ever Jail TermPutin Signs Law on Use of Army to Aid Russians Detained AbroadRussia Tells US to Evacuate Its Diplomats and Citizens From Kyiv

Also: All the news and watercooler chat from Fortune.

Avery Dennison has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

20,000 layoffs, 14 markets exited, one flatter bank—Jane Fraser's Citi playbook is working. Wall Street wants to know what's next.

Voyager Technologies, Inc. (NYSE:VOYG) is among the 10 Best Performing Defense Stocks So Far in 2026. On May 18, Citigroup lifted its price target on the stock to $44 from $36 and reiterated a Buy rating. The adjustment came after the firm revised its models for stocks in the aerospace and defense sector. According to […]

Former SoftBank investors train banks and funds on AI workflows while Wall Street accelerates automation and workforce reductions.

In recent weeks, Citigroup Inc. completed multiple senior unsecured fixed-income offerings, including 5.90% notes due 2056 and zero-coupon notes due 2056, while also securing regulatory approval of its 2025 living will and advancing a private credit partnership with BlackRock’s HPS Investment Partners. The combination of clean regulatory feedback, fresh long-dated funding, and expansion into Asian wealth and private credit highlights how Citigroup is reshaping its business mix toward...

JPMorgan Chase, Bank of America, Citi and Goldman Sachs, additionally, have “adequately addressed” shortcomings found in the banks’ previous emergency wind-down plans, the agencies said Friday.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 12 Best Revenue Growth Stocks to Buy According to Wall Street Analysts. On May 19, Citi initiated coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), giving the stock a Buy rating and setting the price target at $380. The research firm noted that the expanded launch of Amvuttra for […]

C is set to concentrate much of its wealth hiring in Asia, adding nearly 100 private bankers and 400 specialists to strengthen profitability.

JPM and other major U.S. banks cleared Fed and FDIC review of 2025 living wills, easing regulatory concerns and boosting confidence.

If you are trying to work out whether Citigroup's current share price offers value, it helps to start with how the stock has actually been trading. Citigroup closed at US$125.09 most recently, with the stock up 1.4% over the past week, down 2.3% over the past month, up 5.4% year to date and showing a 75.0% return over the last year. These moves have kept Citigroup in focus as investors continue to react to ongoing headlines around large US banks, regulatory developments and the broader...

Investors have had plenty of reasons to question Boeing over the past few years, but Wall Street is starting to separate the company’s defense story from its better-known commercial aviation challenges. Citi is turning more constructive on parts of the aerospace and defense sector after a sharp ...

The AI chip race has produced a handful of clear winners. Broadcom is one of them. But the question heading into its next earnings report is no longer about whether it is a top AI stock to own. The real debate now is: Can a company already pulling in billions from artificial intelligence keep ...